Elevance Health (NYSE:ELV) Updates FY 2026 Earnings Guidance

Elevance Health (NYSE:ELV) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 19.850- for the period, compared to the consensus earnings per share estimate of 25.810. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. UBS Group set a $400.00 price objective on shares of Elevance Health in a research report on Thursday, January 29th. JPMorgan Chase & Co. raised their target price on shares of Elevance Health from $394.00 to $397.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Barclays lowered their target price on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating on the stock in a report on Friday, January 30th. Robert W. Baird increased their price target on shares of Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a report on Thursday. Finally, Evercore lifted their price objective on Elevance Health from $345.00 to $360.00 in a report on Thursday. Eleven equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Elevance Health presently has a consensus rating of “Hold” and a consensus target price of $379.75.

Elevance Health Stock Performance

Shares of ELV opened at $337.47 on Thursday. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. Elevance Health has a 52-week low of $273.71 and a 52-week high of $429.25. The company has a 50-day simple moving average of $308.80 and a 200-day simple moving average of $331.56. The company has a market capitalization of $74.13 billion, a PE ratio of 13.51, a P/E/G ratio of 1.81 and a beta of 0.49.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The business had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company’s revenue was up 1.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities research analysts predict that Elevance Health will post 25.75 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be paid a $1.72 dividend. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 annualized dividend and a yield of 2.0%. Elevance Health’s payout ratio is presently 27.39%.

Trending Headlines about Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 beat and raised full‑year outlook — ELV reported Q1 EPS of $12.58 vs. consensus ~ $10.7–$11.0 and revenue above expectations; management raised 2026 adjusted EPS guidance (now targeting at least $26.75) and signaled at‑least 12% EPS growth target for 2027, supporting upside to earnings expectations. Elevance raises 2026 adjusted EPS outlook
• Positive Sentiment: Margin expansion and operating discipline — Company commentary and coverage highlight improved claims experience, operating discipline and AI integration as drivers of margin expansion that underpin the guidance raise. ELV Q1 deep dive
• Positive Sentiment: Investment income and cash return — Net investment income jumped (reported ~29.7% increase), helping offset membership pressures and higher medical costs; company also declared a $1.72 quarterly dividend (≈2.1% yield), which supports income investors. Zacks: Beats on rising net investment income
• Neutral Sentiment: Analyst action mixed — Robert W. Baird raised its price target from $317 to $331 but maintained a “neutral” rating, implying limited near‑term upside from current levels; other outlets note mixed valuation metrics after the quarter. Benzinga / The Fly: Baird raises PT to $331
• Negative Sentiment: Investor litigation investigation — Law firm Kirby McInerney opened an investigation into potential securities claims involving Elevance and senior management, which could raise legal/oversight risk and increase volatility while the matter develops. GlobeNewswire: Investor alert

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Kemnay Advisory Services Inc. acquired a new position in Elevance Health during the fourth quarter worth approximately $31,000. J.Safra Asset Management Corp acquired a new stake in shares of Elevance Health during the 4th quarter worth $32,000. Jessup Wealth Management Inc purchased a new position in shares of Elevance Health in the 4th quarter worth $45,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Elevance Health in the 4th quarter worth $50,000. Finally, Rossby Financial LCC boosted its holdings in Elevance Health by 85.7% in the fourth quarter. Rossby Financial LCC now owns 156 shares of the company’s stock valued at $55,000 after acquiring an additional 72 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.